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Abstract
Nearly a century ago, Otto Warburg made the ground-breaking observation that cancer cells, unlike normal cells,
prefer a seemingly inefficient mechanism of glucose metabolism: aerobic glycolysis, a phenomenon now referred
to as the Warburg effect. The finding that rapidly proliferating cancer cells favors incomplete metabolism of
glucose, producing large amounts of lactate as opposed to synthesizing ATP to sustain cell growth, has
confounded scientists for years. Further investigation into the metabolic phenotype of cancer has expanded our
understanding of this puzzling conundrum, and has opened new avenues for the development of anti-cancer
therapies. Enhanced glycolytic flux is now known to allow for increased synthesis of intermediates for sustaining
anabolic pathways critical for cancer cell growth. Alongside the increase in glycolysis, cancer cells transform their
mitochondria into synthesis machines supported by augmented glutaminolysis, supplying lipid production, amino
acid synthesis, and the pentose phosphate pathways. Inhibition of several of the key enzymes involved in these
pathways has been demonstrated to effectively obstruct cancer cell growth and multiplication, sensitizing them to
apoptosis. The modulation of various regulatory proteins involved in metabolic processes is central to cancerous
reprogramming of metabolism. The finding that members of one of the major protein families involved in cell
death regulation also aberrantly regulated in cancers, the Bcl-2 family of proteins, are also critical mediators of
metabolic pathways, provides strong evidence for the importance of the metabolic shift to cancer cell survival.
Targeting the anti-apoptotic members of the Bcl-2 family of proteins is proving to be a successful way to selectively
target cancer cells and induce apoptosis. Further understanding of how cancer cells modify metabolic regulation to
increase channeling of substrates into biosynthesis will allow for the discovery of novel drug targets to treat cancer.
In the present review, we focused on the recent developments in therapeutic targeting of different steps in
glycolysis, glutaminolysis and on the metabolic regulatory role of Bcl-2 family proteins.
Background
In 1924, Otto Warburg made the landmark discovery
that, unlike most somatic cells that rely heavily upon
oxidative phosphorylation for efficient and adequate syn-
thesis of ATP to sustain their functions, cancer cells pre-
dominantly depend on aerobic glycolysis and produce
large amounts of lactate [1]. Why cancer cells would
favor a less efficient mechanism for energy production
has long puzzled researchers—a rapidly proliferating cell
would be expected to have extensive energy demands.
Initially, it was surmised that this metabolic switch
resulted from damage to mitochondrial function. For
nearly a century since the first observations of the
“Warburg effect”, increasing evidence has led to the
realization that the metabolic switch in cancer cells is in
fact the result of a highly complex, insidious process of
reprogramming achieving a metabolic state ideal for the
proliferation and sustenance of cancer cells. Historically,
mutations in genes regulating proliferation and growth
signaling were thought to be the primary triggers of
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carcinogenesis, changes in metabolism seen as the cells
simply “keeping up” with the demands of higher multi-
plication rates. However, the finding that many of these
oncogenes moonlight as critical regulators of metabol-
ism and that their dysregulation contributes to altered
metabolic phenotypes that favor growth, has called for a
re-evaluation of metabolic reprogramming as an emer-
ging hallmark of cancer [2, 3]. A significant shift in our
understanding of metabolic state as a central trans-
formative force in cancer cell development was sparked
by observation that changes in metabolism can modulate
a cell’s ability to differentiate [4, 5], diverging from the
paradigm that metabolic reprogramming is an adapta-
tion to mutations in order to maintain biosynthesis and
suggesting that an altered metabolic state can itself en-
hance growth and survival. Continued research in this
area may lead to the development of powerful therapeu-
tics that can selectively target cancer cells by obstructing
their metabolic evolution. The reprogrammed metabol-
ism of cancer cells is instrumental in achieving other
well-described hallmarks of cancer such as limitless pro-
liferation and escape from apoptosis. Many of the me-
tabolites (e.g., (R)-2-hydroxybutyrate, lactate, etc.) that
are specifically elevated in cancer cells promote not only
their proliferation and survival but also prevent their
apoptosis, by either activating the anti-apoptotic Bcl-2
family proteins or increasing their expression.
In this review, we addressed the recent developments
in our understanding on the derangements in cancer cell
glycolysis and glutaminolysis and on the role of Bcl-2
family proteins including Mcl-1, NOXA, Bad, etc., in the
regulation of reprogrammed metabolism in cancer cells.
We highlighted the various suggested novel anti-cancer
therapeutic targets in these metabolic pathways.
The fates of glucose in cancer cell metabolism
When completely oxidized, 1 glucose can provide up to
36 adenosine triphosphate (ATP) molecules, compared
to a meager 2 ATPs per glucose via conversion to lactate
through glycolysis [6]. To reconcile the befuddling dis-
covery that cancer cells sustain rapid proliferative rates
using the comparatively inefficient process of aerobic
glycolysis, Warburg hypothesized that cancer cells may
have defective mitochondria incapable of maintaining
oxidative respiration [7]. However, it has been demon-
strated that cancer cells do not necessarily exhibit com-
promised mitochondrial function [8, 9], suggesting that
another mechanism underlies this metabolic phenotype.
Aerobic glycolysis is indeed sufficient to fuel rapid prolif-
eration, as seen in the case of many unicellular organisms
such as yeast [10, 11]. Cancer cells favoring glycolysis
maintain energy charge, as determined by the ratio of
ATP:ADP and NAD(P)H:NAD(P)+ (NAD is nicotinamide
adenine dinucleotide; NADP is nicotinamide adenine
dinucleotide phosphate), suggesting that energy depletion
does not result as a consequence of this metabolic shift
[12, 13]. This could be due to the fact that cancer cells do
not experience substrate scarcity, and are continually sup-
plied with glucose and other nutrients from the blood.
Additionally, normal cells tightly regulate energy charge
and ATP synthesis to prevent uncontrolled proliferation
even in the presence of abundant resources (Fig. 1). For
example, increases in ATP will negatively feedback on the
glycolytic pathway by inhibiting phosphofructokinase
(PFK) and pyruvate kinase (PK), decreasing the conversion
of glucose to pyruvate and lactate [14, 15]. When ATP is
depleted, increases in AMP will activate AMPK, leading
to the inhibition of anabolic processes such as protein syn-
thesis and triggering catabolism, such as fatty acid oxida-
tion, to replenish ATP [16]. Precise detection of cellular
energy state allows for fine-tuned regulation of anabolic
and catabolic pathways in the cell—interestingly, many
cancer cell types show mutations in the upstream AMPK
kinase LKB1, which is required for phosphorylation and
activation of AMPK [17]. LKB1 is considered to be a
tumor suppressor, and the loss of its function may con-
tribute to carcinogenesis by eliminating the AMPK energy
sensor and dissociating the balance between energy state
and biosynthesis [18, 19]. It has been demonstrated that
LKB1-deficient cancers are susceptible to treatment with
the biguanide phenformin, phenformin selectively indu-
cing apoptosis in these cancer cells as opposed to cancer
cell types harboring other mutations [20]. These findings
suggest that there is potential for the use of phenformin,
and perhaps related compounds, in the treatment of those
cancers with LKB1 defects. Activation of AMPK may also
prove to be a promising target for the development of
novel therapeutics against cancer. Cell culture studies have
shown that activation of AMPK in cancer cells sensitizes
them to chemotherapeutic agents currently used in pa-
tients [21, 22]. AMPK activators could be developed into
powerful therapeutics that could be used in combination
with other drugs to more effectively treat cancer (Fig. 1).
It has also been found that many cancer cell types
preferentially express an isoform of PK, PKM2. Unlike
other isoforms of this enzyme that are consistently in a
tetrameric state and are largely regulated by allosteric in-
hibition by ATP and activation by PEP and fructose 1,6-
bisphosphate, PKM2 can exist in either a highly active
tetrameric state or a less active dimeric state. The PKM2
isoform is expressed in fetal tissues, but is eventually re-
placed with other isoforms later in development [23].
PKM2 offers tumor cells the advantage of increased
metabolic flexibility—this enzyme is chiefly retained in
its dimeric state in cancer cells, allowing glycolytic inter-
mediates to build-up and channel into anabolic pathways
such as phospholipid, nucleotide, and amino acid syn-
thesis that can sustain cellular replication [12, 24]. If
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necessary, however, PKM2 can also switch to its active
tetrameric form in response to modulation by fructose
1,6-bisphosphate in order to increase pyruvate synthesis
and increase ATP production. Studies investigating the
possibility of activating PKM2 to hamper the capacity of
cancer cells to accrue crucial biosynthetic intermediates
have provided evidence that the use of small-molecule
PKM2 activators may indeed be effective in impeding
tumor growth [25, 26].
As mentioned above, cancer cells, which conduct high
levels of glycolysis, produce lactate in large amounts and
this metabolite is transported out of the cell into extra-
cellular environment. Glycolytically produced pyruvate is
converted to lactate by lactate dehydrogenase (LDH),
and this step is essential for the regeneration of NAD+
in the cytosol to let high rates of glycolysis prevail,
which is needed for oncogenesis. There are five different
LDH subtypes (LDH 1–5), which occur as homo- or
hetero-tetramers of muscle-type subunits encoded by
LDH-A gene and heart-type subunits encoded by LDH-B
gene. Cellular levels of lactate are governed by differential
expression of LDH isoforms, the lactate monocarboxylate
transporter (MCT), and the oxidative capacity of cell.
Many studies have shown that several types of cancer cells
require LDH-A gene, which encodes LDH-5 isoenzyme,
for their maintenance and proliferation [27, 28], even
though the precise mechanisms by which LDH-5 pro-
motes cancer progression is not known. LDH-5 expres-
sion by LDH-A gene is under the control of HIF-1α and is
elevated under hypoxic conditions. In fact, it is well
known that HIF-1α expression is elevated in many cancers
and is known to offer protection to cancer cells. Expres-
sion of HIF-1α and LDH-5 are found to be correlated and
associated with poor prognosis of many cancers [29]. Im-
portance of LDH-5 as an anti-cancer target has been ex-
plored extensively, and it has been found that either
Fig. 1 Reprogramming of the glycolytic pathway in cancer cells. Cancer cells rely on increased glycolytic flux, increasing glucose uptake, and
producing large amounts of lactate. The expression of the PKM2 isoform allows for flexibility in that the dimeric form will exhibit decreased
activity, promoting accumulation of glycolytic intermediates that can be shunted into the pentose phosphate pathway and nucleotide synthesis.
Decreased oxidative phosphorylation in normal cells would lead to decreased energy charge and increased AMP, activating AMPK. Cancer cells
often harbor mutations in the upstream AMPK kinase LKB1, without whose phosphorylation activity, AMPK cannot be activated and therefore
cannot inhibit anabolic pathways such as nucleotide synthesis
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suppression of LDH-5 levels by RNAi-based approaches
or by pharmacological inhibition cause significantly atten-
uated cancer cell proliferation and apoptosis [27, 30]. Myc
oncogene, which is activated in many cancers, is known to
regulate the transcription of several cellular proliferation-
related genes and microRNAs and also enhances the ex-
pression of LDH-A [31]. Many cancer cells convert signifi-
cant proportion of glucose to lactate, thus producing an
acidic microenvironment surrounding the cancerous tis-
sue. This acidification of the extracellular microenviron-
ment is known to be advantageous to the tumors, by
favoring invasion and suppression of cytotoxic T lympho-
cytes. Transport of lactate along with a proton, out of the
cell is facilitated by MCT and there are many isoforms of
MCT. It has been shown that inhibition of MCT by
pharmacological agents was effective in curtailing angio-
genesis and tumor progression of gliomas [32]. It has been
suggested recently that MCTs, which are overexpressed in
cancers act as “Trojan horses” as they can be exploited for
transporting bromopyruvate, an anti-cancer agent into
cancer cells to inhibit glycolysis [33]. Thus, overall, it
appears that glycolysis-derived lactate and its handling
by LDH and MCT in cancer cells provide growth
advantage.
Glutaminolysis: the mitochondria as an anabolic apparatus
Apart from glucose, the other major substrate that con-
tributes to energy production is glutamine [34]. Glutami-
nolysis is upregulated in many types of cancer, glutamine
providing the crucial source of nitrogen to these rapidly
proliferating cells for amino acid synthesis via glutamate
production and transamination. Furthermore, instead of
oxidizing glutamine completely to produce ATP, the mito-
chondria of cancer cells shunt glutamine into citrate for
lipid production and for the production of NADPH by
isocitrate dehydrogenase (IDH), and into malate which
can also be converted to pyruvate by malic enzyme and
produce NADPH [35]. Hence, both glucose and glutamine
are utilized to replenish synthetic intermediates as op-
posed to being oxidized for ATP—though it may appear
that this form of metabolism is inefficient, the increased
production of ATP does not meet the requirements of a
rapidly multiplying cell as effectively. As a result of this
switch to increased glutamine dependence by the mito-
chondria, the diminished contribution of glucose to the
tricarboxylic acid (TCA) cycle is well-compensated for by
contributions from glutamine, and the mitochondria are
transformed into apparatuses for the synthesis of building
blocks required to sustain rapid cell division (Fig. 2). This
Fig. 2 Increased glutaminolysis and the role of the mitochondria in cancer cells. The mitochondria of cancer cells switch from the canonical
function of oxidative phosphorylation and ATP production to synthesis of anabolic intermediates that can be utilized for lipid and amino acid
synthesis. This is supported by high rates of glutaminolysis, Glutamine is converted to glutamate by glutaminase, and glutamate is then transaminated
into α-ketoglutarate, which contributes to citrate and malate synthesis. Both of these metabolites can then be exported from the mitochondria, malate
converted to pyruvate and then lactate to produce NADPH. Citrate can also be metabolized to α-ketoglutarate, synthesizing NADPH, or alternatively
be channeled into lipid synthesis. PDH pyruvate dehydrogenase complex, MDH malate dehydrogenase, SDH succinate dehydrogenase, α-KGDH α-
ketoglutarate dehydrogenase complex, CS citrate synthase, TA transaminase, GDC glutamate dehydrogenase
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mitochondrial reprogramming results from increased ex-
pression of the oncogenic transcription factor Myc, which
increases expression of glutaminase and glutamine trans-
porters to support increased glutaminolysis, and also aug-
ments expression of lactate dehydrogenase A (LDH-A)
which allows shunting of glucose-derived pyruvate away
from the mitochondria and into lactate [31, 36].
This glutamine “addiction” observed in cancer cells
suggests that targeting any of the pathways involved in
maintaining glutamine metabolism would exhaust can-
cer cells of a key substrate supply. Since increased
NADPH production is one of the major benefits of this
altered glutamine metabolism, a likely candidate for
novel drug design is IDH. Furthermore, IDH activity is
important to maintain redox regulation and scavenge re-
active oxygen species (ROS) that may otherwise cause
extensive damage and trigger apoptosis. Cancer cells
with ablated expression of the mitochondrial isoform
IDH2, had diminished capacity to form tumors when
grafted into mice as compared with cancer cells where
IDH2 expression was retained [37]. Interestingly, in
many cancers such as glioma, colorectal cancer, and
acute myeloid leukemia, IDH is mutated such that its ac-
tivity is enhanced and it produces an “oncometabolite”
called (R)-2-hydroxyglutarate from α-ketoglutarate. This
mutation allows for increased flux of glutamine into
lipid production, and (R)-2-hydroxyglutarate itself is
thought to inhibit oxidative phosphorylation by inhibit-
ing complexes of the electron transport chain, favoring
channeling of glutamine away from oxidation and to-
wards anabolic pathways [38, 39]. Additionally, mutated
IDH was found to inhibit the expression of HNF4α, an
important regulator of hepatocyte differentiation and
proliferation, allowing liver progenitor cells to evade
differentiation and maintain high replicative rates [40].
Targeting mutant IDH and decreasing its activity can ef-
fectively impose differentiation upon cancer cells, limit-
ing their replicative potential and rendering them more
susceptible to drugs that induce apoptosis [41]. Finally,
tumors harboring IDH mutations are especially reliant
on glutamine metabolism—another promising drug
target is glutaminase, whose inhibition would starve
cancer cells of glutamine, essentially shutting down
biosynthesis [42, 43].
The dual personalities of the Bcl-2 family proteins
Some of the most groundbreaking discoveries highlight-
ing the importance of metabolic reprogramming in can-
cer development were those implicating members of the
Bcl-2 family of proteins as metabolic regulators. Bcl-2
family proteins have long been recognized as crucial medi-
ators of mitochondrial apoptotic signaling, also referred to
as intrinsic apoptosis [44, 45]. These proteins share close
homologous domains known as Bcl-2 homology (BH)
domains—several of the multi-domain members may con-
tain 3–4 BH domains, Mcl-1, Bcl-2, and Bcl-xL being
some of the anti-apoptotic proteins of this variety and Bak
and Bax the pro-apoptotic. Some of these proteins also
contain transmembrane domains, allowing them to dir-
ectly embed into the mitochondrial and endoplasmic
reticulum membranes [46]. Several pro-apoptotic single
domain proteins, the BH3-only proteins, contain only the
BH3 domain considered to be the minimal death domain,
and play significant roles in determining the balance be-
tween pro- and anti-apoptotic signaling [47]. The specific
interactions amongst different Bcl-2 proteins are what ul-
timately decide whether the intrinsic cell death pathway is
activated. The pro-apoptotic Bak and Bax, both trans-
membrane proteins, can oligomerize to form pores, or
mitochondrial outer membrane permeabilization (MOMP)
that allows release of mitochondrial cytochrome c into
the cytoplasm, triggering apoptosis [48, 49]. The anti-
apoptotic Bcl-2 proteins do not form oligomers, and can
complex with Bak or Bax preventing their oligomeriza-
tion. Some of the BH3-only proteins will bind anti-
apoptotic Bcl-2 proteins, sequester them away from Bax/
Bak and in this way negate their anti-apoptotic effect.
Other BH3-only proteins can interact with Bak and Bax,
promoting their oligomerization [50].
Anti-apoptotic Bcl-2 family proteins such as Bcl-2,
Bcl-xL, and Mcl-1 are frequently upregulated in various
forms of cancer, promoting tumorigenesis and resistance
to chemotherapy. In recent years, significant progress
has been made in the development of a novel class of
anti-cancer drugs that specifically inhibit the anti-
apoptotic Bcl-2 family proteins, or act as BH3 mimetics.
These drugs have a critical advantage over classical cyto-
toxic therapies that do not possess the same degree of
specificity for cancerous cells and have many toxic side
effects [51–53]. The fascinating discovery that many of
the Bcl-2 family proteins are also the key modulators of
metabolism, and that their role as apoptotic mediators is
in fact a secondary function, suggests that cells naturally
link dysregulation of metabolism or the unavailability of
substrates to cell death, a process that involves nutrient
dependent changes in the expression and activity of
pro- (PUMA, NOXA, Bad, and Bim) and anti-(Mcl-1)
apoptotic proteins. It is also possible that cancer cell re-
programming involves altering Bcl-2 proteins to sustain a
metabolic phenotype suitable for increased growth. The
earliest confirmation of a metabolic role for Bcl-2 proteins
was the finding that BH3-only protein BAD resides in a
complex with glucokinase [54]. Glucokinase is crucial for
detection of glucose in hepatocytes and pancreatic B cells,
and due to its high Km for glucose and absence of product
feedback inhibition, the glucokinase reaction is entirely
substrate driven and acts as an ideal substrate sensor.
BAD will activate glucokinase via direct interaction, which
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is promoted by phosphorylation of BAD by kinases such
as Akt. When bound to glucokinase, BAD’s pro-apoptotic
functions are defused. However, dephosphorylated BAD
will dissociate from glucokinase, freeing it to bind with
anti-apoptotic Bcl-2 or Bcl-xL and promote apoptosis. In
certain types of cancers, it has been demonstrated that
BAD phosphorylation is increased due to the increased ac-
tivities of upstream kinases, and that inhibition of BAD
phosphorylation decreases cancer cell survival [55–57].
Sequestration of BAD to the glucokinase complex will
not only prevent its pro-apoptotic functions, but will
also promote increased glucokinase activity and gly-
colysis, a key metabolic shift that favors biosynthesis
and proliferation. Although dephosphorylation of BAD
alone is not adequate to trigger apoptosis, it shifts the
balance towards cell death and uncouples the favorable
metabolic signal of high glucose flux from regulation
of cell survival.
Besides the modification of expression and activity of
Bcl-2 family proteins, metabolic reprogramming in can-
cer cells ensures the supply of necessary metabolite
building blocks for cell proliferation. Thus, the elevated
glycolysis ensures the supply of glycolytic intermediates
glycerol-3-phosphate and dihydroxyacetone phosphate,
needed for the biosynthesis of phospholipids, the major
constituents of cell membranes. Similarly, reprogram-
ming of lipid metabolism ensures the synthesis of
fatty acids and other lipids, needed for membranogen-
esis. In fact, the upregulated glutaminolysis not only
supports the energy needs of the cancer cells but also
provides the needed precursors for lipogenesis via cit-
rate cycle, as mentioned above in the glutaminolysis
section.
Another BH3-only member of the Bcl-2 family in-
volved in metabolic regulation is NOXA. The cyclin-
dependant kinase 5 (CDK5) will phosphorylate NOXA
in the presence of high glucose. Phosphorylated NOXA
localizes to the cytoplasm and is incapable of executing
its pro-apoptotic functions—instead, it complexes with
Mcl-1L and promotes increased glucose metabolism and
augments flux through the pentose phosphate pathway,
supporting nucleotide synthesis [58]. Indeed, NOXA is
constitutively expressed in cancer cells, and many can-
cers exhibit increased CDK5 activity that is important
for tumor growth and survival of thyroid and neuroen-
docrine cancers [59, 60]. Modification of the metabolic
and apoptotic roles of Bcl-2 family proteins is one of the
major mechanisms by which cancer cells achieve the
metabolic shift necessary to meet the growth require-
ments. The effectiveness of therapeutics targeting this
family of proteins suggests that drugs that can both in-
crease cancer cell susceptibility to apoptosis and undo
tumorigenic metabolic reprogramming may prove to be
much more potent in treating cancer.
Conclusions
A consistent feature of tumor metabolism is increased
glycolysis and glutaminolysis, both of which are used to
supply the intermediates required to sustain amino acid
synthesis, the pentose phosphate pathway, and lipid pro-
duction. These metabolic outcomes are achieved via sev-
eral mechanisms—however, strategies targeting cancer
cell metabolism and inhibiting the Warburg effect are
showing great promise as powerful, novel therapies to
target cancer. Nearly a century after the first observa-
tions that cancer cells maintain altered metabolic fea-
tures, the significance of metabolic reprogramming in
carcinogenesis and its relevance to anti-cancer drug de-
sign continues to grow. Further research in this field will
shed light on tumor progression, and how to most ef-
fectively “starve” cancer.
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